Together, these findings suggest that antagonizing miR-181 by inhibitor-lincRNAp21 and DNMT may hinder the neurotoxicity of P13K/Akt/mTOR signaling pathways and reduce the activate microglia and neuroinflammation in PD pathogenesis. This evidence concerns the gene AKT1 and Parkinson disease.